By Ludwig Burger
FRANKFURT (Reuters) -Roche’s third-quarter gross sales acquired a currency-adjusted 9%, defeating market assumptions, on better prescriptions of once-monthly haemophilia shot Hemlibra and only recently launched eye treatment Vabysmo.
Group gross sales of 15.14 billion Swiss francs ($ 17.46 billion) exceeded an consultants’ settlement quote of 14.9 billion francs, primarily based upon LSEG data.
The Swiss drugmaker declared on Wednesday it anticipates growth in 2024 modified earnings per share within the “high single-digit range”, leaving out the results of cash swings and backbone of tax obligation conflicts in 2023.
($ 1 = 0.8671 Swiss francs)
(Reporting by Ludwig Burger, Editing by Rachel More)
